Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Mar 2023
Historique:
received: 01 02 2023
revised: 28 02 2023
accepted: 01 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Millions of people have been vaccinated with Gam-COVID-Vac but fine specificities of induced antibodies have not been fully studied. Plasma from 12 naïve and 10 coronavirus disease 2019 (COVID-19) convalescent subjects was obtained before and after two immunizations with Gam-COVID-Vac. Antibody reactivity in the plasma samples (n = 44) was studied on a panel of micro-arrayed recombinant folded and unfolded severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins and 46 peptides spanning the spike protein (S) and by immunoglobulin G (IgG) subclass enzyme-linked immunosorbent assay (ELISA). The ability of Gam-COVID-Vac-induced antibodies to inhibit binding of the receptor-binding domain (RBD) to its receptor angiotensin converting enzyme 2 (ACE2) was investigated in a molecular interaction assay (MIA). The virus-neutralizing capacity of antibodies was studied by the pseudo-typed virus neutralization test (pVNT) for Wuhan-Hu-1 and Omicron. We found that Gam-COVID-Vac vaccination induced significant increases of IgG

Identifiants

pubmed: 36982183
pii: ijms24065104
doi: 10.3390/ijms24065104
pmc: PMC10049224
pii:
doi:

Substances chimiques

Epitopes 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Protein Subunits 0
Spike Glycoprotein, Coronavirus 0
Immunoglobulin G 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Viravaxx
ID : AG
Organisme : Megagrant of the Government of the Russian Federation
ID : 14.W03.31.0024
Organisme : Russian Science Foundation
ID : 21-15-00286

Références

NPJ Vaccines. 2021 Aug 16;6(1):104
pubmed: 34400651
Allergy. 2021 Mar;76(3):878-883
pubmed: 32734595
Front Cell Infect Microbiol. 2022 Jun 16;12:928279
pubmed: 35782120
Allergy. 2022 May;77(5):1616-1620
pubmed: 35188670
Clin Transl Immunology. 2021 Jan 31;10(2):e1245
pubmed: 33552508
Viruses. 2021 Jan 29;13(2):
pubmed: 33572857
Front Immunol. 2022 Aug 09;13:938378
pubmed: 36016943
Allergy. 2021 Jun;76(6):1922-1924
pubmed: 33340417
Allergy. 2022 Aug;77(8):2431-2445
pubmed: 35357709
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Nat Commun. 2021 Jul 26;12(1):4598
pubmed: 34312390
Allergy. 2021 Dec;76(12):3627-3641
pubmed: 33999439
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Allergy. 2022 Jan;77(1):230-242
pubmed: 34453317
Front Immunol. 2021 Dec 13;12:766821
pubmed: 34966387
Vaccines (Basel). 2021 Jul 12;9(7):
pubmed: 34358195
Front Immunol. 2021 Apr 28;12:647934
pubmed: 33995366
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Int J Mol Sci. 2022 Feb 14;23(4):
pubmed: 35216194
Sci Rep. 2022 Feb 2;12(1):1727
pubmed: 35110645
Front Immunol. 2022 May 11;13:833085
pubmed: 35634315
Clin Exp Allergy. 2011 Oct;41(10):1468-77
pubmed: 21711470
Cell Rep. 2022 Aug 16;40(7):111220
pubmed: 35963244
Allergy. 2017 Aug;72(8):1156-1173
pubmed: 28152201
Int J Mol Sci. 2022 Apr 14;23(8):
pubmed: 35457159
EClinicalMedicine. 2022 Mar 24;46:101360
pubmed: 35340627
Clin Microbiol Infect. 2022 Mar;28(3):398-404
pubmed: 34838783
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
EBioMedicine. 2019 Dec;50:421-432
pubmed: 31786130
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Int J Mol Sci. 2023 Mar 10;24(6):
pubmed: 36982424
Lancet Reg Health Eur. 2021 Dec;11:100241
pubmed: 34746910
Elife. 2022 Jan 24;11:
pubmed: 35072628
Phytother Res. 2020 Nov;34(11):2783-2785
pubmed: 32648294
Pak J Pharm Sci. 2021 Jul;34(4):1469-1484
pubmed: 34799323
Front Immunol. 2021 Mar 26;12:613045
pubmed: 33841395
EClinicalMedicine. 2021 Oct;40:101126
pubmed: 34541480

Auteurs

Maria Byazrova (M)

National Research Center-Institute of Immunology FMBA of Russia, 115478 Moscow, Russia.
Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
Department of Immunology, Peoples' Friendship University of Russia (RUDN University) of Ministry of Science and Higher Education of the Russian Federation, 117198 Moscow, Russia.

Pia Gattinger (P)

Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.

Ekaterina Astakhova (E)

National Research Center-Institute of Immunology FMBA of Russia, 115478 Moscow, Russia.
Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.

Gerhard Hofer (G)

Department of Materials and Environmental Chemistry, University of Stockholm, 106 91 Stockholm, Sweden.

Musa Khaitov (M)

National Research Center-Institute of Immunology FMBA of Russia, 115478 Moscow, Russia.
Department of Immunology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia.

Alexander Filatov (A)

National Research Center-Institute of Immunology FMBA of Russia, 115478 Moscow, Russia.
Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.

Rudolf Valenta (R)

National Research Center-Institute of Immunology FMBA of Russia, 115478 Moscow, Russia.
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, 119435 Moscow, Russia.
Karl Landsteiner University of Health Sciences, 3500 Krems, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH